BillionToOne is transforming the landscape of molecular diagnostics through its patented molecular counting platform. By achieving a level of sensitivity that far exceeds traditional methods, the company is drastically improving outcomes for prenatal screening and oncology diagnostics.
Operating with the agility of a startup despite its public market status, BillionToOne fosters an environment of radical transparency. They attract top-tier scientific and engineering talent who are passionate about applying cutting-edge technology to solve some of the most critical challenges in human health.